Agios Pharmaceuticals (AGIO) Other Non Operating Income (2021 - 2026)

Agios Pharmaceuticals' Other Non Operating Income history runs 6 years deep, the most recent figure standing at $119000.0 for Q1 2026.

• Quarterly Other Non Operating Income fell 90.5% year-over-year to $119000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $822000.0 (down 86.54% YoY) and the FY2025 annual result came in at $2.0 million, down 69.85% from the prior year.
• Other Non Operating Income was $119000.0 for Q1 2026 at Agios Pharmaceuticals, up from $113000.0 in the prior quarter.
• Across five years, Other Non Operating Income topped out at $3.0 million in Q1 2022 and bottomed at $67000.0 in Q3 2025.
• A 5-year average of $1.3 million and a median of $1.4 million in 2022 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2024 — Other Non Operating Income surged 37.81% — and 2025, when it slumped 95.94%.
• Agios Pharmaceuticals' Other Non Operating Income stood at $1.4 million in 2022, then grew by 26.23% to $1.7 million in 2023, then slipped by 5.25% to $1.6 million in 2024, then plunged by 93.04% to $113000.0 in 2025, then advanced by 5.31% to $119000.0 in 2026.
• Business Quant data shows AGIO's Other Non Operating Income at $119000.0 in Q1 2026, $113000.0 in Q4 2025, and $67000.0 in Q3 2025.